Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record, with a small difference in title or year; 30 of the 31 references it cites were found in a registry or an index; 52 of the 68 sources its claims cite were checked for support.

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis

Open access

Abstract

BACKGROUND: Neoadjuvant use of immune checkpoint inhibitors (ICIs) before liver resection results in pathological tumour regression in patients with hepatocellular carcinoma. We aimed to describe the characteristics of pathological responses after preoperative ICI therapy for hepatocellular carcinoma and to evaluate the association between the depth of tumour regression and relapse-free survival. METHODS: In this cross-trial, patient-level analysis, we performed a pooled analysis of data from patients with hepatocellular carcinoma receiving ICI therapy before liver resection as part of a global collaborative consortium (NeoHCC) of five phase 1 and 2 clinical trials and standardised observational protocols conducted in 12 tertiary referral centres across the USA, UK, and Taiwan. Eligible patients were adults (aged ≥18 years) diagnosed with hepatocellular carcinoma by tissue core biopsy before treatment initiation, a Liver Imaging Reporting and Data System score of 5 on imaging, or both, with an Eastern Cooperative Oncology Group performance status score of 0-1, and no extrahepatic spread or previous ICI treatment. Pathological response was measured as the percentage of non-viable tumour in the resected surgical specimen, with major pathological response corresponding to at least 70% tumour regression and pathological complete response corresponding to 100% tumour regression. We correlated pathological response with radiological overall response using RECIST criteria (version 1.1) and relapse-free survival, and evaluated the threshold of tumour regression that could be optimally associated with relapse-free survival. FINDINGS: At data cutoff on Jan 31, 2024, 111 patients were included in the study, of whom data on pathological response were available for 104 (94%) patients. Patients received treatment from Oct 5, 2017, to Nov 15, 2023, mostly ICI combinations (76 [69%]), for a median of 1·4 months (IQR 0·7-2·9). 87 (78%) patients were men and 24 (22%) were women. Most patients had underlying viral chronic liver disease (73 [66%]) and Barcelona Clinic Liver Cancer stage A hepatocellular carcinoma (61 [55%]), without portal vein thrombosis (87 [78%]). We observed major pathological response in 33 (32%) patients and pathological complete response in 19 (18%) patients. Radiological overall response was associated with major pathological response, with 23 (74%) of 31 patients with radiological response showing major pathological response compared with ten (14%) of 73 patients without radiological response (p<0·0001). However, ten (30%) of 33 major pathological responses were not predicted by radiological response. After a median follow-up of 27·2 months (95% CI 22·3-32·1), median relapse-free survival for the whole cohort was 43·6 months (95% CI 28·3-not evaluable). Relapse-free survival was significantly longer in patients with major pathological response than in those who did not have a major pathological response (not reached [95% CI not evaluable-not evaluable] vs 28·3 months [12·8-43·8]; hazard ratio 0·26 [0·10-0·66]; p=0·0024) and in patients with pathological complete response than in those who did not have a pathological complete response (NR [95% CI not evaluable-not evaluable] vs 32·8 months [15·0-50·5]; 0·19 [0·05-0·78]; p=0·010). Unbiased recursive partitioning of the cohort for the risk of relapse, death, or both identified a threshold of 90% as the optimal cutoff of pathological tumour regression to predict improved relapse-free survival. INTERPRETATION: The extent of tumour regression following neoadjuvant ICI therapy could identify patients with improved relapse-free survival following liver resection. The threshold of at least 90% tumour regression should be validated for its surrogate role for relapse-free survival in phase 3 randomised controlled trials. FUNDING: None.

Overview

CoChat Summary

TL;DR

In a cross-trial, patient-level pooled analysis of 111 patients with hepatocellular carcinoma receiving neoadjuvant immune checkpoint inhibitors before liver resection, major pathological response occurred in 33 (32%) and pathological complete response in 19 (18%). Depth of pathological response was associated with improved relapse-free survival, and an optimal 90% tumour-regression threshold was identified for predicting relapse-free survival.

Key findings

  • Among 104 pathologically evaluable patients, major pathological response (≥70% non-viable tumour) occurred in 33 (32%) and pathological complete response (100%) in 19 (18%); the distribution was bimodal, with 85 (82%) of 104 samples showing either <25% or >75% response.
  • After median follow-up of 27·2 months (95% CI 22·3–32·1), median relapse-free survival for the whole cohort was 43·6 months (95% CI 28·3–not evaluable). Major pathological response was associated with longer relapse-free survival (not reached vs 28·3 months; HR 0·26 [95% CI 0·10–0·66]; p=0·0024), as was pathological complete response (not reached vs 32·8 months; HR 0·19 [0·05–0·78]; p=0·010).
  • Radiological overall response was associated with major pathological response: 23 (74%) of 31 patients with radiological response vs 10 (14%) of 73 without (p<0·0001), but 10 (30%) of 33 major pathological responses were not predicted by radiological response.
  • Unbiased recursive partitioning identified 90% as the optimal pathological tumour-regression cutoff for predicting relapse-free survival; Youden’s index on the ROC curve for 24-month relapse-free survival estimated an optimal threshold of 92·5% (sensitivity 93·8%, specificity 29·0%), while the 70% threshold had sensitivity 84·4% and specificity 39·1%.

Methods

  • Design: cross-trial, patient-level pooled analysis within the NeoHCC consortium, including five phase 1 and 2 clinical trials and standardised observational protocols at 12 tertiary referral centres in the USA, UK, and Taiwan; data cutoff was Jan 31, 2024, with 111 patients treated from Oct 5, 2017, to Nov 15, 2023.
  • Participants: adults aged ≥18 years with hepatocellular carcinoma diagnosed by tissue core biopsy before treatment initiation or LI-RADS score 5 on imaging, ECOG performance status 0–1, and no extrahepatic spread or previous immune checkpoint inhibitor treatment. Pathological response was measured as percentage of non-viable tumour in the resected specimen; major pathological response was ≥70% regression and pathological complete response was 100% regression.
  • Analysis: Kaplan–Meier estimates and Cox regression models for relapse-free survival and time to relapse; radiological response assessed by RECIST version 1.1 (modified RECIST in a subset); recursive partitioning and ROC/Youden’s index to identify the optimal response threshold; frailty models and centre-level cluster correction were applied.

Limitations

  • Paper-stated limitations include heterogeneous tumour presentations (from resectable BCLC stage A to upfront unresectable tumours), varied ICI-based treatments and durations, different timing of response assessment across protocols, sample size insufficient to definitively confirm surrogacy, inability to perform internal random cross-validation of recursive partitioning models, absence of central histological review, no pooled translational biomarker analysis, and no prospectively enrolled control group.
  • Evident from the text: the analysis pools early-phase and observational data without a randomised comparator, and overall survival data were not mature, with only 13 (12%) deaths recorded, limiting assessment of longer-term survival outcomes.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(24)00457-1

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1: Study profile
Figure 1: Study profileCC BY · PubMed Central
Figure 2: Pathological responses of surgical samples from patients after neoadjuvant immunotherapy and association with radiological responses (A) Pathological responses assessed in the surgical samples by percentage of tumour regression (n=104). (B) The correlation between change in tumour size based on radiological assessment (RECIST criteria [version 1.1]) and pathological response of each surgical specimen. (C) Waterfall plot for the depth of pathological response, with different bar colours according to radiological response as per RECIST criteria (version 1.1); the dashed line represents major pathological response (70% tumour regression). RECIST=Response Evaluation Criteria in Solid Tumours.
Figure 2: Pathological responses of surgical samples from patients after neoadjuvant immunotherapy and association with radiological responses (A) Pathological responses assessed in the surgical samples by percentage of tumour regression (n=104). (B) The correlation between change in tumour size based on radiological assessment (RECIST criteria [version 1.1]) and pathological response of each surgical specimen. (C) Waterfall plot for the depth of pathological response, with different bar colours according to radiological response as per RECIST criteria (version 1.1); the dashed line represents major pathological response (70% tumour regression). RECIST=Response Evaluation Criteria in Solid Tumours.CC BY · PubMed Central
Figure 3: Association between major pathological response and pathological complete response and relapse-free survival (A) Forest plot representing the HRs for relapse-free survival associated with different thresholds of pathological responses in the whole cohort (n=104). (B) Kaplan–Meier curves for relapse-free survival according to the occurrence of major pathological response; vertical dashed denote censored patients (C). Forest plot showing the association between the occurrence of major pathological response and improvement in relapse-free survival within each cohort of the NeoHCC study consortium; the size of the shapes (squares and diamond) denote effects size. Patients with available pathological assessment data were included (n=104). Imperial College London and St Bartholomew’s Hospital were part of the same clinical trial (NCT03682276).12 Patients treated at Mount Sinai Hospital within the clinical trial8 or the observational clinical study20 were centrally assessed for pathological response and data were pooled together. (D) Kaplan–Meier curves for relapse-free survival according to the occurrence of pathological complete response; vertical dashed denote censored patients. HR=hazard ratio.
Figure 3: Association between major pathological response and pathological complete response and relapse-free survival (A) Forest plot representing the HRs for relapse-free survival associated with different thresholds of pathological responses in the whole cohort (n=104). (B) Kaplan–Meier curves for relapse-free survival according to the occurrence of major pathological response; vertical dashed denote censored patients (C). Forest plot showing the association between the occurrence of major pathological response and improvement in relapse-free survival within each cohort of the NeoHCC study consortium; the size of the shapes (squares and diamond) denote effects size. Patients with available pathological assessment data were included (n=104). Imperial College London and St Bartholomew’s Hospital were part of the same clinical trial (NCT03682276).12 Patients treated at Mount Sinai Hospital within the clinical trial8 or the observational clinical study20 were centrally assessed for pathological response and data were pooled together. (D) Kaplan–Meier curves for relapse-free survival according to the occurrence of pathological complete response; vertical dashed denote censored patients. HR=hazard ratio.CC BY · PubMed Central

Verification

Claims the paper makes

15 Valid · 3 Not valid · 9 Not checked · 86 Own results and interpretations

52 more claims · 1 with their cited sources checked

Create a free account to see all 113 claims and to verify the 2 references still open.

See all claims — free account
  • It may state two separate claims as one. 22
  • Probably not a substantial claim. 35
  • Borderline: one of the tests for a substantial claim is unclear. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 31 references

Cited by

See all 90

Metadata

Authors
D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., Pai, M., Goldin, R. D., Ward, S. C., Fiel, M. I., Shu, D. H., Su, Y.-Y., Cortellini, A., Baretti, M., Anders, R., Yarchoan, M., Hsu, C., Marron, T. U., & Pinato, D. J.
Affiliations
  • Imperial College London (GB)
  • Mount Sinai Hospital (US)
  • Barts Health NHS Trust (GB)
  • National Health Service (GB)
  • Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
  • St Mary's Hospital (GB)
  • Icahn School of Medicine at Mount Sinai (US)
  • Johns Hopkins University (US)
  • Kaohsiung Medical University (TW)
  • Università Campus Bio-Medico (IT)
  • National Taiwan University (TW)
Corresponding author
Pinato, David J
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2024-11
Volume
25
Issue
11
Pages
1465-1475
ISSN
1470-2045 (ISSN-L)
OpenAlex
W4403559173
Cited by
90
References
31
Citations by year
2026: 42 · 2025: 46 · 2024: 2
FWCI
23.26
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Oncology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
  • NHRI Institutional Repository (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
Funders
  • Airc Italian Foundation for Cancer Research (MFAG 25697)
  • Cancer Research UK (RCCPDB\u2013Nov21/100008)
  • Bristol-Myers Squibb (NCT03682276, NCT03916627)
  • Foundation for Liver Research
  • Wellcome Trust (PS3416)
  • Associazione Italiana per la Ricerca sul Cancro
  • European Association for the Study of the Liver
  • Imperial Experimental Cancer Medicine Centre
  • Cancer Treatment and Research Trust
  • NIHR Imperial Biomedical Research Centre
  • National Institute for Health and Care Research
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
Keywords
hepatocellular carcinoma, pathological response, tumor regression, hepatectomy, relapse-free survival, pathological complete response, major pathological response, predictive biomarkers, immune-related adverse events, Barcelona Clinic Liver Cancer staging, immune checkpoint inhibitor combination, tumor-infiltrating lymphocytes
MeSH terms
Immune Checkpoint Inhibitors, Adult, Aged, Female, Hepatectomy, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. https://app.cochat.ai/papers/10.1016/s1470-2045(24)00457-1
The paper
D'Alessio, A., Stefanini, B., Blanter, J., Adegbite, B., Crowley, F., Yip, V., Slater, S., Fulgenzi, C. A. M., Celsa, C., Manfredi, G. F., Pai, M., Goldin, R. D., Ward, S. C., Fiel, M. I., Shu, D. H., Su, Y.-Y., Cortellini, A., Baretti, M., Anders, R., . . . Pinato, D. J. (2024). Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(24)00457-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.